Skip to content
The Nexus
BUSINESSJun 9 · 06:48 UTCSTAT NEWSAndrew Joseph

STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B

GSK agreed to acquire Nuvalent, a cancer-focused biotech company, for $10.6 billion in a cash deal. The transaction includes a 26% premium over Nuvalent’s 30-day average share price, with GSK paying $124 per share and spending approximately $9.4 billion in cash.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
GSKorganizationNuvalentorganizationcancertopiconcologytopicSTAT+organization
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting